Bridges Investment Counsel Has Trimmed By $1.16 Million Its Abbott Labs Com (ABT) Position; Last Week Sarepta Therapeutics, Inc. (SRPT) Coverage

January 14, 2018 - By Adrian Mccoy

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. Sarepta Therapeutics had 95 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Equal-Weight” rating by Morgan Stanley given on Thursday, July 20. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Tuesday, July 18 by Leerink Swann. Needham maintained the shares of SRPT in report on Tuesday, September 20 with “Buy” rating. The rating was maintained by RBC Capital Markets on Friday, September 1 with “Buy”. The rating was upgraded by Cowen & Co on Tuesday, September 20 to “Outperform”. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Underperform” rating given on Wednesday, March 23 by JMP Securities. On Wednesday, August 26 the stock rating was upgraded by RBC Capital Markets to “Outperform”. The company was downgraded on Monday, January 18 by Piper Jaffray. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “” rating by SunTrust on Friday, August 7. Wedbush upgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Friday, October 2 to “Outperform” rating. See Sarepta Therapeutics, Inc. (NASDAQ:SRPT) latest ratings:

09/01/2018 Broker: JMP Securities Rating: Buy New Target: $60.0
03/01/2018 Broker: Janney Capital Rating: Buy New Target: $75.0 Initiate
01/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $75 Initiates Coverage On
26/10/2017 Broker: Needham Rating: Buy New Target: $75.0 Maintain
26/10/2017 Broker: Barclays Capital Rating: Equal-Weight Old Target: $46 New Target: $49 Maintain
26/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $60.0 Maintain
17/10/2017 Broker: Robert W. Baird Rating: Buy New Target: $101.0 Maintain
09/10/2017 Broker: Leerink Swann Rating: Buy New Target: $66.0 Maintain
02/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $64.0 Maintain
02/10/2017 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Old Target: $33 Upgrade

Bridges Investment Counsel Inc decreased Abbott Labs Com (ABT) stake by 37.34% reported in 2017Q3 SEC filing. Bridges Investment Counsel Inc sold 21,950 shares as Abbott Labs Com (ABT)’s stock declined 3.42%. The Bridges Investment Counsel Inc holds 36,842 shares with $1.97 million value, down from 58,792 last quarter. Abbott Labs Com now has $102.42 billion valuation. The stock decreased 0.19% or $0.11 during the last trading session, reaching $58.84. About 6.32 million shares traded or 6.93% up from the average. Abbott Laboratories (NYSE:ABT) has risen 15.90% since January 14, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories has $90 highest and $4 lowest target. $51.95’s average target is -11.71% below currents $58.84 stock price. Abbott Laboratories had 92 analyst reports since July 24, 2015 according to SRatingsIntel. RBC Capital Markets maintained Abbott Laboratories (NYSE:ABT) rating on Friday, October 9. RBC Capital Markets has “Outperform” rating and $51 target. On Thursday, June 29 the stock rating was reinitiated by Jefferies with “Buy”. The firm has “Buy” rating by Jefferies given on Tuesday, September 5. The stock has “Buy” rating by Jefferies on Tuesday, September 13. The rating was maintained by BMO Capital Markets on Monday, October 2 with “Hold”. The firm earned “Overweight” rating on Tuesday, January 2 by Morgan Stanley. The firm has “Overweight” rating by Barclays Capital given on Thursday, September 28. BMO Capital Markets maintained Abbott Laboratories (NYSE:ABT) on Thursday, October 19 with “Market Perform” rating. BMO Capital Markets maintained Abbott Laboratories (NYSE:ABT) on Thursday, August 31 with “Hold” rating. The rating was upgraded by Barclays Capital on Wednesday, October 7 to “Overweight”.

Investors sentiment decreased to 0.87 in Q3 2017. Its down 0.01, from 0.88 in 2017Q2. It dropped, as 47 investors sold ABT shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. 1.21 billion shares or 0.79% less from 1.22 billion shares in 2017Q2 were reported. Maryland Cap holds 3.16% of its portfolio in Abbott Laboratories (NYSE:ABT) for 384,225 shares. Cape Cod Five Cents Financial Bank holds 60,691 shares. Kistler has 4,487 shares. Rathbone Brothers Public Lc reported 219,445 shares stake. Moreover, Parametrica Management has 0.12% invested in Abbott Laboratories (NYSE:ABT) for 5,352 shares. Rench Wealth Management stated it has 1.74% of its portfolio in Abbott Laboratories (NYSE:ABT). Tower Rech Cap Ltd Llc (Trc) accumulated 6,408 shares. Tompkins Fincl Corp owns 24,452 shares for 0.31% of their portfolio. Patten And Patten Tn holds 0.1% or 17,614 shares. Moreover, Eaton Vance Management has 0.36% invested in Abbott Laboratories (NYSE:ABT) for 2.61 million shares. Commerce Savings Bank stated it has 0.29% of its portfolio in Abbott Laboratories (NYSE:ABT). Orrstown Financial Services has invested 1.15% of its portfolio in Abbott Laboratories (NYSE:ABT). Schroder Inv Mngmt Grp Inc reported 0.01% in Abbott Laboratories (NYSE:ABT). Sta Wealth Ltd Limited Liability Company stated it has 0.1% in Abbott Laboratories (NYSE:ABT). Opus Capital Ltd Liability Company has invested 0.14% in Abbott Laboratories (NYSE:ABT).

Since August 1, 2017, it had 0 buys, and 6 selling transactions for $22.86 million activity. 62,460 shares were sold by Salvadori Daniel Gesua Sive, worth $3.31M. Bracken Sharon J sold $98,323 worth of Abbott Laboratories (NYSE:ABT) on Tuesday, August 1. Fussell Stephen R sold $9.73M worth of stock or 196,550 shares. The insider Contreras Jaime sold 52,700 shares worth $2.74 million.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on January, 24 before the open. They expect $0.73 EPS, up 12.31% or $0.08 from last year’s $0.65 per share. ABT’s profit will be $1.27 billion for 20.15 P/E if the $0.73 EPS becomes a reality. After $0.66 actual EPS reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 10.61% EPS growth.

Investors sentiment increased to 2.88 in Q3 2017. Its up 1.36, from 1.52 in 2017Q2. It improved, as 24 investors sold Sarepta Therapeutics, Inc. shares while 27 reduced holdings. 63 funds opened positions while 84 raised stakes. 51.70 million shares or 25.22% more from 41.29 million shares in 2017Q2 were reported. Creative Planning reported 103,756 shares stake. Fisher Asset Management Limited Liability Corporation has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Highbridge Cap Mngmt Ltd Liability Com reported 20,326 shares. Wells Fargo & Mn invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Guggenheim Capital Ltd Liability Company reported 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Sphera Funds Mgmt Limited invested in 2.49% or 384,997 shares. Voya Investment Mngmt Ltd Liability Com reported 629,053 shares. Utd Cap Advisers holds 0.01% or 25,471 shares. Tourbillon Prtnrs Limited Partnership has invested 1.68% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Lehman Fincl Res accumulated 6,392 shares. Kingdon Mgmt Llc stated it has 0.03% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Raymond James Financial Serv owns 27,596 shares. Vanguard Grp Inc owns 4.94 million shares or 0.01% of their US portfolio. Legal & General Gp Public Ltd has invested 0% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Hikari owns 25,000 shares for 0.15% of their portfolio.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $3.98 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

The stock increased 4.29% or $2.53 during the last trading session, reaching $61.52. About 2.22M shares traded or 23.78% up from the average. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 96.82% since January 14, 2017 and is uptrending. It has outperformed by 80.12% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>